Cargando…
Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine
Oseltamivir (OA), an ethyl ester prodrug of oseltamivir carboxylate (OC), is clinically used as a potent and selective inhibitor of neuraminidase. Chinese medicines have been advocated to combine with conventional drug for avian influenza. The current study aims to investigate the potential pharmaco...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912631/ https://www.ncbi.nlm.nih.gov/pubmed/24527044 http://dx.doi.org/10.1155/2014/354172 |
_version_ | 1782302110732255232 |
---|---|
author | Chang, Qi Wo, Siukwan Ngai, Karry L. K. Wang, Xiaoan Fok, Benny Ngan, Teresa M. Wong, Vivian T. Chan, Thomas Y. K. Lee, Vincent H. L. Tomlinson, Brian Chan, Paul K. S. Chow, Moses S. S. Zuo, Zhong |
author_facet | Chang, Qi Wo, Siukwan Ngai, Karry L. K. Wang, Xiaoan Fok, Benny Ngan, Teresa M. Wong, Vivian T. Chan, Thomas Y. K. Lee, Vincent H. L. Tomlinson, Brian Chan, Paul K. S. Chow, Moses S. S. Zuo, Zhong |
author_sort | Chang, Qi |
collection | PubMed |
description | Oseltamivir (OA), an ethyl ester prodrug of oseltamivir carboxylate (OC), is clinically used as a potent and selective inhibitor of neuraminidase. Chinese medicines have been advocated to combine with conventional drug for avian influenza. The current study aims to investigate the potential pharmacokinetic and pharmacodynamic interactions of a Chinese medicine formula, namely, Yin Qiao San and Sang Ju Yin (CMF1), commonly used for anti-influenza in combination with OA in both rat and human, and to reveal the underlined mechanisms. It was found that although C (max), AUC and urinary recovery of OC, as well as metabolic ratio (AUC(OC)/AUC(OA)), were significantly decreased in a dose-dependent manner following combination use of CMF1 and OA in rat studies (P < 0.01), such coadministration in 14 healthy volunteers only resulted in a trend of minor decrease in the related parameters. Further mechanistic studies found that although CMF1 could reduce absorption and metabolism of OA, it appears to enhance viral inhibition of OA (P < 0.01). In summary, although there was potential interaction between OA and CMF1 found in rat studies, its clinical impact was expected to be minimal. The coadministration of OA and CMF1 at the clinical recommended dosages is, therefore, considered to be safe. |
format | Online Article Text |
id | pubmed-3912631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39126312014-02-13 Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine Chang, Qi Wo, Siukwan Ngai, Karry L. K. Wang, Xiaoan Fok, Benny Ngan, Teresa M. Wong, Vivian T. Chan, Thomas Y. K. Lee, Vincent H. L. Tomlinson, Brian Chan, Paul K. S. Chow, Moses S. S. Zuo, Zhong Evid Based Complement Alternat Med Research Article Oseltamivir (OA), an ethyl ester prodrug of oseltamivir carboxylate (OC), is clinically used as a potent and selective inhibitor of neuraminidase. Chinese medicines have been advocated to combine with conventional drug for avian influenza. The current study aims to investigate the potential pharmacokinetic and pharmacodynamic interactions of a Chinese medicine formula, namely, Yin Qiao San and Sang Ju Yin (CMF1), commonly used for anti-influenza in combination with OA in both rat and human, and to reveal the underlined mechanisms. It was found that although C (max), AUC and urinary recovery of OC, as well as metabolic ratio (AUC(OC)/AUC(OA)), were significantly decreased in a dose-dependent manner following combination use of CMF1 and OA in rat studies (P < 0.01), such coadministration in 14 healthy volunteers only resulted in a trend of minor decrease in the related parameters. Further mechanistic studies found that although CMF1 could reduce absorption and metabolism of OA, it appears to enhance viral inhibition of OA (P < 0.01). In summary, although there was potential interaction between OA and CMF1 found in rat studies, its clinical impact was expected to be minimal. The coadministration of OA and CMF1 at the clinical recommended dosages is, therefore, considered to be safe. Hindawi Publishing Corporation 2014 2014-01-09 /pmc/articles/PMC3912631/ /pubmed/24527044 http://dx.doi.org/10.1155/2014/354172 Text en Copyright © 2014 Qi Chang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chang, Qi Wo, Siukwan Ngai, Karry L. K. Wang, Xiaoan Fok, Benny Ngan, Teresa M. Wong, Vivian T. Chan, Thomas Y. K. Lee, Vincent H. L. Tomlinson, Brian Chan, Paul K. S. Chow, Moses S. S. Zuo, Zhong Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title | Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title_full | Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title_fullStr | Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title_full_unstemmed | Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title_short | Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine |
title_sort | bench to bed evidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and chinese medicine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912631/ https://www.ncbi.nlm.nih.gov/pubmed/24527044 http://dx.doi.org/10.1155/2014/354172 |
work_keys_str_mv | AT changqi benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT wosiukwan benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT ngaikarrylk benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT wangxiaoan benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT fokbenny benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT nganteresam benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT wongviviant benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT chanthomasyk benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT leevincenthl benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT tomlinsonbrian benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT chanpaulks benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT chowmosesss benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine AT zuozhong benchtobedevidencesforpharmacokineticandpharmacodynamicinteractionsinvolvingoseltamivirandchinesemedicine |